837377-20-5

Basic information

• Product Name: Cyclohexanol, 4-aMino-1-Methyl-, hydrochloride, trans- (9CI)
• Synonyms: Cyclohexanol, 4-aMino-1-Methyl-, hydrochloride, trans- (9CI);Cyclohexanol, 4-aMino-1-Methyl-, hydrochloride (1:1), trans-;(1r,4r)-4-aMino-1-Methylcyclohexan-1-ol hydrochloride;4-AMino-1-Methylcyclohexanol hydrochloride;trans-4-Amino-1-methylcyclohexanol hydrochloride
• CAS NO: 837377-20-5
• Molecular Formula: C7H16ClNO
• Molecular Weight: 165.66104
• Mol File: 837377-20-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclohexanol, 4-aMino-1-Methyl-, hydrochloride, trans- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanol, 4-aMino-1-Methyl-, hydrochloride, trans- (9CI)(837377-20-5)
• EPA Substance Registry System: Cyclohexanol, 4-aMino-1-Methyl-, hydrochloride, trans- (9CI)(837377-20-5)

Safety Data

• Hazardous Substances Data: 837377-20-5(Hazardous Substances Data)

Usage

General Description

Cyclohexanol, 4-amino-1-methyl-, hydrochloride, trans- (9CI) is a chemical compound with a molecular formula C7H15NOCl. It is a derivative of cyclohexanol, containing an amino and methyl group. Cyclohexanol, 4-amino-1-methyl-, hydrochloride, trans- (9CI) is in the trans configuration, with the hydrochloride salt form. The trans configuration refers to the arrangement of molecules around a double bond, where the substituents on either side of the double bond are on opposite sides of the plane. This chemical may have various applications in pharmaceuticals, biochemical research, and other industries.

Upstream product

• 233764-31-3 (cis-1,4)-(4-hydroxy-4-methyl-cyclohexyl)carbamic acid tert-butyl ester 
• 917-54-4 methyllithium 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 233764-31-3 tert-butyl (trans-4-hydroxy-4-methylcyclohexyl)carbamate 
• 233764-31-3 tert-butyl N-(4-hydroxy-4-methylcyclohexyl)carbamate 
• 233764-31-3 tert-butyl ((1r,4r)-4-hydroxy-4-methylcyclohexyl)carbamate 
• 233764-31-3 tert-butyl ((1s,4s)-4-hydroxy-4-methylcyclohexyl)carbamate 

Relevant articles and documents

SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR

Disclosed is a compound of Formula 1, and pharmaceutically acceptable salts thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with mTOR.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.

NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS

This invention relates to nicotinamide derivatives of formula (I) and to pharmaceutical compositions containing, and the uses of such derivatives as PDE4 inhibitors wherein R7 is attached to the 3-or 4-position of the phenyl ring and is S(O)pR8, R8 is (C1-C4)alkyl optionally substituted by (C3-C6)cycloalkyl; m is 0 or 1; L is a (C3-C8)carbocyclic non-aromatic ring; and the remaining variables are as defined in the claims.